Catabasis Pharmaceuticals Receives $39,600,000 Series A Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=185dbbe5-4be9-40ad-9eb9-d66080961dcc&Preview=1 -
Date
4/21/2010 -
Company Name
Catabasis Pharmaceuticals -
Mailing Address
161 1st St. Cambridge, MA 02142 -
Company Description
At Catabasis we are dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. We have assembled a team of highly motivated and experienced scientists who are committed to improving the lives of patients. -
Website
http://www.catabasispharma.com/index.html -
Transaction Type
Venture Equity -
Transaction Amount
$39,600,000 -
Transaction Round
Series A -
Proceeds Purposes
Proceeds from the financing will be used to advance Catabasis’ lead program targeting type 2 diabetes, and to further the development of the company’s proprietary platform technology in additional inflammatory and metabolic diseases. -
M&A Terms
-
Venture Investor
SV Life Sciences -
Venture Investor
Clarus Ventures -
Venture Investor
MedImmune Ventures -
Venture Investor
Advanced Technology Ventures
